Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.37 |
| ▸ | THRA | P10827 | 11/20 | 0.36 |
| ▸ | THRB | P10828 | 11/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137902 | 0.92 | ACSS2 (0.35) | ACSS2THRATHRBRAF1BRAF | |
| SCHEMBL5137904 | 0.85 | ACSS2 (0.33) | ACSS2THRATHRB | |
| SCHEMBL3142133 | 0.83 | POLB (0.45) | ACSS2THRATHRBRAF1BRAF | |
| SCHEMBL3130577 | 0.82 | ACSS2 (0.40) | ACSS2THRATHRB | |
| SCHEMBL3137672 | 0.82 | RAF1 (0.37) | ACSS2THRATHRBRAF1BRAF | |
| SCHEMBL3142258 | 0.82 | THRA (0.36) | ACSS2THRATHRB | |
| SCHEMBL3136098 | 0.81 | ACSS2 (0.35) | ACSS2THRATHRB | |
| SCHEMBL3128023 | 0.81 | ACSS2 (0.35) | ACSS2THRATHRB | |
| SCHEMBL3127197 | 0.80 | THRA (0.35) | ACSS2THRATHRB | |
| SCHEMBL3133600 | 0.80 | ACSS2 (0.40) | ACSS2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | claimed |
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | ACSS2 519/4885THRA 4/4885THRB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.